Moderna R&D day: $1 billion in cost cuts, 10 product launches
WEBSep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid...
News Details - Moderna
WEBMar 26, 2024 · The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.
News Details - Moderna
WEBMar 27, 2024 · Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development. Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024.
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBAugust 22, 2024. Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent...
News Details - Moderna
WEBSep 11, 2023 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines …
Moderna says its RSV shot is 50% effective across a second season
WEBNEW YORK, June 26 (Reuters) - Moderna Inc (MRNA.O) respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.
News Details - Moderna
WEBJan 8, 2024 · Moderna will enter the RSV market with a strong competitive profile as the only pre-filled syringe product available at the time of launch, along with robust efficacy data, a well-established safety and tolerability profile, and widespread consumer awareness and demand established in 2023.
Moderna, Inc. (MRNA) Latest Stock News & Headlines - Yahoo …
WEBGet the latest Moderna, Inc. (MRNA) stock news and headlines to help you in your trading and investing decisions.
Moderna forecasts lower sales next year, shares near four-year low
WEBSept 12 (Reuters) - Moderna (MRNA.O) pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its...
Moderna jumps as vaccine shows benefit in head and neck cancer …
WEBApril 9 (Reuters) - Moderna (MRNA.O) shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck (MRK.N) showed positive response in an...